相关实验视频
Updated: May 6, 2026

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.9K
胺在败血性休克中的使用:对两项随机试验的后期分析
Jacob Vine1, John H Lee2,3, Max S Kravitz4,5
1Center for Resuscitation Science, Beth Israel Deaconess Medical Center, Boston, MA, USA. jvine@bidmc.harvard.edu.
Critical care (London, England)
|February 6, 2024
概括
在性休克患者中,提氨酸的使用改善了存活率和功能. 胺缺乏症患者的益处更为明显,突出了其在重症监护中的重要性.
科学领域:
- 关键护理医学 关键护理医学
- 腎臟病學 (nephrology) 是一種醫學.
- 营养生物化学 营养生物化学
背景情况:
- 败血性休克对功能和生存构成重大风险.
- 胺 (维生素B1) 在细胞代谢中起着至关重要的作用.
- 以前的研究表明,在败血症休克中,胺的潜在益处.
研究的目的:
- 评估胺管理对脏保护和败血症休克患者的死亡率的影响.
- 分析整体和胺缺乏的败血症休克群体的结果.
主要方法:
- 后期分析结合了来自两个II期临床试验 (NCT01070810,NCT03550794) 的患者级数据.
- 主要结局:没有替代疗法 (RRT) 的生存率.
- 分析按整体队列和胺缺乏小组 (胺<8nmol/L) 分层.
主要成果:
- 整体队列:胺与更高的存活率和无RRT (aOR: 2.05) 和不需要RRT (aOR: 2.59) 相关.
- 胺缺乏队列:胺与活着和没有RRT (aOR:8.17) 和医院生存率 (aOR:6.84) 的几率明显更高有关.
- 观察到显著的相互作用,表明基线胺缺乏改变了治疗效果 (p=0.016活着/无RRT,p=0.019生存).
结论:
- 提氨酸的使用与在败血症休克中改善生存率和脏结果有关.
- 胺的有益作用在患有先前存在的胺缺乏症的患者中得到放大.
- 这些发现支持考虑在败血性休克管理中补充胺,特别是在缺陷患者中.
相关概念视频
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
260
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
260
Therapeutic Drug Monitoring: Overview and Classification
648
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
648
Therapeutic Drug Monitoring: Affecting Factors
438
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
438
Therapeutic Drug Monitoring: Drug Analysis Methods
349
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
349
Acute Kidney Injury III: Clinical Manifestations
1.8K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.8K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
582
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
582

